Guardant Health(GH) - 2025 Q1 - Quarterly Results

Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data Raises 2025 revenue guidance to $880 to$890 million, representing growth of 19% to 20% PALO ALTO, Calif. April 30, 2025 – Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights ...